Insider trades

Hohl Benjamin, CFO of Enliven Therapeutics ELVN, has filed 0 purchases and 57 sales on the open market. Over the past 12 months that comes to a net sale of $559.4K. The latest trade was on 06/17.

Hohl Benjamin

CFO
First filing
23/02/27
Trades
153 trades
Buys / sales
0 / 57
12-month net buying
−$559.4K
Last trade
06/17

Trading activity

Transactions

Trade type
ELVN
Open-market sale10b5-1 plan06/1706/226,018 sh3 trades$43.80avg.$263,575.77−10.6%
Open-market sale03/0603/1010,000 sh$29.58$295,800−16.4%
Open-market sale10b5-1 plan25/09/2925/10/013,250 sh$20.40$66,300−12.4%
Open-market sale10b5-1 plan25/08/2725/08/293,250 sh$20.63$67,047.5−12.4%
ELVN
Open-market sale10b5-1 plan25/07/2825/07/303,250 sh2 trades$20.47avg.$66,517.75−12.4%
Open-market sale10b5-1 plan25/07/1025/07/141,000 sh$22.66$22,660−4.2%
ELVN
Open-market sale10b5-1 plan25/06/2725/07/013,250 sh2 trades$20.91avg.$67,953.4−12.4%
Open-market sale10b5-1 plan25/06/1325/06/173,000 sh$22.55$67,650−11.5%
Open-market sale10b5-1 plan25/05/2725/05/293,250 sh$16.18$52,585−12.4%
ELVN
Open-market sale10b5-1 plan25/04/2825/04/303,250 sh2 trades$18.69avg.$60,740.36−12.4%
Open-market sale10b5-1 plan25/03/2725/03/313,250 sh$21.33$69,322.5−12.4%
Open-market sale10b5-1 plan25/03/2425/03/261,000 sh$22.50$22,500−4.2%
Open-market sale10b5-1 plan25/02/2725/03/033,250 sh$20.41$66,332.5−20.0%
Open-market sale10b5-1 plan25/02/0525/02/071,000 sh$22.52$22,520−7.1%
Open-market sale10b5-1 plan25/01/2725/01/293,250 sh$21.59$70,167.5−20.0%
Open-market sale10b5-1 plan25/01/0325/01/071,000 sh$25.04$25,040−7.1%
ELVN
Open-market sale10b5-1 plan24/12/27–24/12/3024/12/314,250 sh2 trades$22.23avg.$94,461.5−100.0%
ELVN
Open-market sale10b5-1 plan24/11/2724/12/025,250 sh2 trades$24.89avg.$130,695−100.0%
ELVN
Open-market sale10b5-1 plan24/10/2824/10/306,250 sh2 trades$28.55avg.$178,465.5−100.0%
Open-market sale10b5-1 plan24/10/1824/10/22814 sh$30.00$24,420−100.0%